Skip to main content
Top
Published in: Clinical and Translational Oncology 6/2017

01-06-2017 | Research Article

Results of a multicenter survey showing interindividual variability among neurosurgeons when deciding on the radicality of surgical resection in glioblastoma highlight the need for more objective guidelines

Authors: J. Capellades, P. Teixidor, G. Villalba, C. Hostalot, G. Plans, R. Armengol, S. Medrano, A. Estival, R. Luque, S. Gonzalez, M. Gil-Gil, S. Villa, J. Sepulveda, J. J. García-Mosquera, C. Balana

Published in: Clinical and Translational Oncology | Issue 6/2017

Login to get access

Abstract

Purpose

We assessed agreement among neurosurgeons on surgical approaches to individual glioblastoma patients and between their approach and those recommended by the topographical staging system described by Shinoda.

Methods

Five neurosurgeons were provided with pre-surgical MRIs of 76 patients. They selected the surgical approach [biopsy, partial resection, or gross total resection (GTR)] that they would recommend for each patient. They were blinded to each other’s response and they were told that patients were younger than 50 years old and without symptoms. Three neuroradiologists classified each case according to the Shinoda staging system.

Results

Biopsy was recommended in 35.5–82.9%, partial resection in 6.6–32.9%, and GTR in 3.9–31.6% of cases. Agreement among their responses was fair (global kappa = 0.28). Nineteen patients were classified as stage I, 14 as stage II, and 43 as stage III. Agreement between the neurosurgeons and the recommendations of the staging system was poor for stage I (kappa = 0.14) and stage II (kappa = 0.02) and fair for stage III patients (kappa = 0.29). An individual analysis revealed that in contrast to the Shinoda system, neurosurgeons took into account T2/FLAIR sequences and gave greater weight to the involvement of eloquent areas.

Conclusions

The surgical approach to glioblastoma is highly variable. A staging system could be used to examine the impact of extent of resection, monitor post-operative complications, and stratify patients in clinical trials. Our findings suggest that the Shinoda staging system could be improved by including T2/FLAIR sequences and a more adequate weighting of eloquent areas.
Appendix
Available only for authorised users
Literature
1.
go back to reference Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96. doi:10.1056/NEJMoa043330.CrossRefPubMed Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96. doi:10.​1056/​NEJMoa043330.CrossRefPubMed
3.
go back to reference Shinoda J, Sakai N, Murase S, Yano H, Matsuhisa T, Funakoshi T. Selection of eligible patients with supratentorial glioblastoma multiforme for gross total resection. J Neurooncol. 2001;52(2):161–71.CrossRefPubMed Shinoda J, Sakai N, Murase S, Yano H, Matsuhisa T, Funakoshi T. Selection of eligible patients with supratentorial glioblastoma multiforme for gross total resection. J Neurooncol. 2001;52(2):161–71.CrossRefPubMed
4.
go back to reference Balana C, De Las Penas R, Sepulveda JM, Gil-Gil MJ, Luque R, Gallego O, et al. Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial. J Neurooncol. 2016;127(3):569–79. doi:10.1007/s11060-016-2065-5.CrossRefPubMed Balana C, De Las Penas R, Sepulveda JM, Gil-Gil MJ, Luque R, Gallego O, et al. Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial. J Neurooncol. 2016;127(3):569–79. doi:10.​1007/​s11060-016-2065-5.CrossRefPubMed
5.
go back to reference Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159–74.CrossRefPubMed Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159–74.CrossRefPubMed
6.
go back to reference Stummer W, van den Bent MJ, Westphal M. Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion. Acta Neurochir (Wien). 2011;153(6):1211–8. doi:10.1007/s00701-011-1001-x.CrossRef Stummer W, van den Bent MJ, Westphal M. Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion. Acta Neurochir (Wien). 2011;153(6):1211–8. doi:10.​1007/​s00701-011-1001-x.CrossRef
8.
go back to reference Marko NF, Weil RJ, Schroeder JL, Lang FF, Suki D, Sawaya RE. Extent of resection of glioblastoma revisited: personalized survival modeling facilitates more accurate survival prediction and supports a maximum-safe-resection approach to surgery. J Clin Oncol. 2014;32(8):774–82. doi:10.1200/JCO.2013.51.8886.CrossRefPubMedPubMedCentral Marko NF, Weil RJ, Schroeder JL, Lang FF, Suki D, Sawaya RE. Extent of resection of glioblastoma revisited: personalized survival modeling facilitates more accurate survival prediction and supports a maximum-safe-resection approach to surgery. J Clin Oncol. 2014;32(8):774–82. doi:10.​1200/​JCO.​2013.​51.​8886.CrossRefPubMedPubMedCentral
9.
go back to reference Grabowski MM, Recinos PF, Nowacki AS, Schroeder JL, Angelov L, Barnett GH, et al. Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma. J Neurosurg. 2014;121(5):1115–23. doi:10.3171/2014.7.JNS132449.CrossRefPubMed Grabowski MM, Recinos PF, Nowacki AS, Schroeder JL, Angelov L, Barnett GH, et al. Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma. J Neurosurg. 2014;121(5):1115–23. doi:10.​3171/​2014.​7.​JNS132449.CrossRefPubMed
11.
go back to reference Keles GE, Anderson B, Berger MS. The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere. Surg Neurol. 1999;52(4):371–9.CrossRefPubMed Keles GE, Anderson B, Berger MS. The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere. Surg Neurol. 1999;52(4):371–9.CrossRefPubMed
12.
go back to reference Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, Raza SM, Pascual-Gallego M, Ibrahim A, et al. Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-oncology. 2014;16(1):113–22. doi:10.1093/neuonc/not137.CrossRefPubMed Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, Raza SM, Pascual-Gallego M, Ibrahim A, et al. Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-oncology. 2014;16(1):113–22. doi:10.​1093/​neuonc/​not137.CrossRefPubMed
13.
go back to reference Roder C, Bisdas S, Ebner FH, Honegger J, Naegele T, Ernemann U, et al. Maximizing the extent of resection and survival benefit of patients in glioblastoma surgery: high-field iMRI versus conventional and 5-ALA-assisted surgery. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2014;40(3):297–304. doi:10.1016/j.ejso.2013.11.022. Roder C, Bisdas S, Ebner FH, Honegger J, Naegele T, Ernemann U, et al. Maximizing the extent of resection and survival benefit of patients in glioblastoma surgery: high-field iMRI versus conventional and 5-ALA-assisted surgery. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2014;40(3):297–304. doi:10.​1016/​j.​ejso.​2013.​11.​022.
15.
go back to reference Chaichana KL, Halthore AN, Parker SL, Olivi A, Weingart JD, Brem H, et al. Factors involved in maintaining prolonged functional independence following supratentorial glioblastoma resection. Clinical article. J Neurosurg. 2011;114(3):604–12. doi:10.3171/2010.4.JNS091340.CrossRefPubMed Chaichana KL, Halthore AN, Parker SL, Olivi A, Weingart JD, Brem H, et al. Factors involved in maintaining prolonged functional independence following supratentorial glioblastoma resection. Clinical article. J Neurosurg. 2011;114(3):604–12. doi:10.​3171/​2010.​4.​JNS091340.CrossRefPubMed
17.
go back to reference Chaichana K, Parker S, Olivi A, Quinones-Hinojosa A. A proposed classification system that projects outcomes based on preoperative variables for adult patients with glioblastoma multiforme. J Neurosurg. 2010;112(5):997–1004. doi:10.3171/2009.9.JNS09805.CrossRefPubMed Chaichana K, Parker S, Olivi A, Quinones-Hinojosa A. A proposed classification system that projects outcomes based on preoperative variables for adult patients with glioblastoma multiforme. J Neurosurg. 2010;112(5):997–1004. doi:10.​3171/​2009.​9.​JNS09805.CrossRefPubMed
18.
go back to reference Chaichana KL, Garzon-Muvdi T, Parker S, Weingart JD, Olivi A, Bennett R, et al. Supratentorial glioblastoma multiforme: the role of surgical resection versus biopsy among older patients. Ann Surg Oncol. 2011;18(1):239–45. doi:10.1245/s10434-010-1242-6.CrossRefPubMed Chaichana KL, Garzon-Muvdi T, Parker S, Weingart JD, Olivi A, Bennett R, et al. Supratentorial glioblastoma multiforme: the role of surgical resection versus biopsy among older patients. Ann Surg Oncol. 2011;18(1):239–45. doi:10.​1245/​s10434-010-1242-6.CrossRefPubMed
19.
go back to reference Kubben PL, ter Meulen KJ, Schijns OE, ter Laak-Poort MP, van Overbeeke JJ, van Santbrink H. Intraoperative MRI-guided resection of glioblastoma multiforme: a systematic review. Lancet Oncol. 2011;12(11):1062–70.CrossRefPubMed Kubben PL, ter Meulen KJ, Schijns OE, ter Laak-Poort MP, van Overbeeke JJ, van Santbrink H. Intraoperative MRI-guided resection of glioblastoma multiforme: a systematic review. Lancet Oncol. 2011;12(11):1062–70.CrossRefPubMed
20.
go back to reference Kuhnt D, Becker A, Ganslandt O, Bauer M, Buchfelder M, Nimsky C. Correlation of the extent of tumor volume resection and patient survival in surgery of glioblastoma multiforme with high-field intraoperative MRI guidance. Neuro-oncology. 2011;13(12):1339–48. doi:10.1093/neuonc/nor133.CrossRefPubMedPubMedCentral Kuhnt D, Becker A, Ganslandt O, Bauer M, Buchfelder M, Nimsky C. Correlation of the extent of tumor volume resection and patient survival in surgery of glioblastoma multiforme with high-field intraoperative MRI guidance. Neuro-oncology. 2011;13(12):1339–48. doi:10.​1093/​neuonc/​nor133.CrossRefPubMedPubMedCentral
22.
go back to reference Stummer W, Tonn JC, Mehdorn HM, Nestler U, Franz K, Goetz C, et al. Counterbalancing risks and gains from extended resections in malignant glioma surgery: a supplemental analysis from the randomized 5-aminolevulinic acid glioma resection study. Clinical article. J Neurosurg. 2011;114(3):613–23. doi:10.3171/2010.3.JNS097.CrossRefPubMed Stummer W, Tonn JC, Mehdorn HM, Nestler U, Franz K, Goetz C, et al. Counterbalancing risks and gains from extended resections in malignant glioma surgery: a supplemental analysis from the randomized 5-aminolevulinic acid glioma resection study. Clinical article. J Neurosurg. 2011;114(3):613–23. doi:10.​3171/​2010.​3.​JNS097.CrossRefPubMed
23.
go back to reference Carrabba G, Fava E, Giussani C, Acerbi F, Portaluri F, Songa V, et al. Cortical and subcortical motor mapping in rolandic and perirolandic glioma surgery: impact on postoperative morbidity and extent of resection. J Neurosurg Sci. 2007;51(2):45–51.PubMed Carrabba G, Fava E, Giussani C, Acerbi F, Portaluri F, Songa V, et al. Cortical and subcortical motor mapping in rolandic and perirolandic glioma surgery: impact on postoperative morbidity and extent of resection. J Neurosurg Sci. 2007;51(2):45–51.PubMed
24.
25.
go back to reference Ferroli P, Schiariti M, Finocchiaro G, Salmaggi A, Castiglione M, Acerbi F, et al. Operability of glioblastomas: “sins of action” versus “sins of non-action”. Neurol Sci Off J Ital Neurol So Ital Soc Clin Neurophys. 2013;34(12):2107–16. doi:10.1007/s10072-013-1345-5. Ferroli P, Schiariti M, Finocchiaro G, Salmaggi A, Castiglione M, Acerbi F, et al. Operability of glioblastomas: “sins of action” versus “sins of non-action”. Neurol Sci Off J Ital Neurol So Ital Soc Clin Neurophys. 2013;34(12):2107–16. doi:10.​1007/​s10072-013-1345-5.
26.
go back to reference Teo C, Broggi M. Surgical outcome of patients considered to have “inoperable” tumors by specialized pediatric neuro-oncological multidisciplinary teams. Child’s Nerv Syst ChNS Off J Int Soc Pediatr Neurosurg. 2010;26(9):1219–25. doi:10.1007/s00381-010-1199-6.CrossRef Teo C, Broggi M. Surgical outcome of patients considered to have “inoperable” tumors by specialized pediatric neuro-oncological multidisciplinary teams. Child’s Nerv Syst ChNS Off J Int Soc Pediatr Neurosurg. 2010;26(9):1219–25. doi:10.​1007/​s00381-010-1199-6.CrossRef
27.
go back to reference McGirt MJ, Chaichana KL, Gathinji M, Attenello FJ, Than K, Olivi A, et al. Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg. 2009;110(1):156–62.CrossRefPubMed McGirt MJ, Chaichana KL, Gathinji M, Attenello FJ, Than K, Olivi A, et al. Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg. 2009;110(1):156–62.CrossRefPubMed
28.
30.
go back to reference Stummer W, Meinel T, Ewelt C, Martus P, Jakobs O, Felsberg J, et al. Prospective cohort study of radiotherapy with concomitant and adjuvant temozolomide chemotherapy for glioblastoma patients with no or minimal residual enhancing tumor load after surgery. J Neurooncol. 2012;108(1):89–97. doi:10.1007/s11060-012-0798-3.CrossRefPubMedPubMedCentral Stummer W, Meinel T, Ewelt C, Martus P, Jakobs O, Felsberg J, et al. Prospective cohort study of radiotherapy with concomitant and adjuvant temozolomide chemotherapy for glioblastoma patients with no or minimal residual enhancing tumor load after surgery. J Neurooncol. 2012;108(1):89–97. doi:10.​1007/​s11060-012-0798-3.CrossRefPubMedPubMedCentral
Metadata
Title
Results of a multicenter survey showing interindividual variability among neurosurgeons when deciding on the radicality of surgical resection in glioblastoma highlight the need for more objective guidelines
Authors
J. Capellades
P. Teixidor
G. Villalba
C. Hostalot
G. Plans
R. Armengol
S. Medrano
A. Estival
R. Luque
S. Gonzalez
M. Gil-Gil
S. Villa
J. Sepulveda
J. J. García-Mosquera
C. Balana
Publication date
01-06-2017
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 6/2017
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-016-1598-6

Other articles of this Issue 6/2017

Clinical and Translational Oncology 6/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine